bullish
Resapp Health
ResApp’s Confirmatory Study Fails, Resulting in Pfizer’s Lower A$0.146 Offer
The revised SID provides no obvious way for Pfizer to pull its offer. At the last close of A$0.125, the gross spread to the unconfirmed data offer price of A$0.146 is 16.8%.
Event-Driven
373 Views, 21 Jun 2022 19:28
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- Unlimited Research Summaries
- Personalised Alerts
- Custom Watchlists
- Company Data & News
- Events & Webinars
Trusted by:
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Top 5%
Arun George
IPOs and Catalysts/Events
Global Equity Research Ltd
Price Chart(Sign Up to Access)
- Merger Arb Mondays (18 Jul) - Link Admin, AOF, DTAC/True, Ramsay Health, ResApp, Infomedia18 Jul 2022
- Merger Arb Mondays (04 Jul) - Link Admin, Ramsay, DTAC/True, Australian Unity Office Fund, Yashili04 Jul 2022
- Merger Arb Mondays (27 Jun) - Ramsay Health, Link Admin, Link Net, True/DTAC, ResApp, Giordano27 Jun 2022
- ResApp’s Confirmatory Study Fails, Resulting in Pfizer’s Lower A$0.146 Offer21 Jun 2022
- ResApp Draws a Revised Binding Offer from Pfizer14 Jun 2022
x